Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

39.98
+0.41001.04%
Post-market: 40.630.6500+1.63%16:19 EDT
Volume:7.58M
Turnover:303.57M
Market Cap:28.88B
PE:-85.06
High:40.97
Open:40.45
Low:39.50
Close:39.57
52wk High:42.50
52wk Low:14.50
Shares:722.41M
Float Shares:581.00M
Volume Ratio:1.10
T/O Rate:1.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:6.83
PE(LYR):-74.04

Loading ...

Earning Preview: Roivant Sciences Ltd. revenue is expected to decrease by 92.94%, institutional views are bullish

Earnings Agent
·
May 13

Immunovant to report fourth-quarter, fiscal-year results, give business update on conference call

Reuters
·
May 12

Roivant schedules quarterly, fiscal-year results call and webcast

Reuters
·
May 12

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

THOMSON REUTERS
·
May 12

Immunovant director Robert Graham Susman sells 2,502 shares for $67,988.34

Reuters
·
May 02

Zura Bio names Marlyn Mathew principal financial, accounting officer after CFO exit

Reuters
·
Apr 24

Roivant CEO Matthew Gline disposes of 289,774 common shares for $8.45 million

Reuters
·
Apr 21

Roivant Sciences (ROIV) Gets a Buy from J.P. Morgan

TIPRANKS
·
Apr 18

Roivant Sciences Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Apr 17

Roivant Sciences Ltd : Piper Sandler Raises Target Price to $40 From $22

THOMSON REUTERS
·
Apr 16

Roivant Chief Accounting Officer Jennifer Humes disposes 13,538 shares for $384,278

Reuters
·
Apr 11

Roivant Sciences price target raised to $34 from $30 at Jefferies

TIPRANKS
·
Apr 07

Roivant Sciences (ROIV) Is Up 6.8% After Mixed Autoimmune Trial Updates - Has The Bull Case Changed?

Simply Wall St.
·
Apr 04

Immunovant CEO Eric Venker disposes of common shares worth $8.5 million

Reuters
·
Apr 04

Ro says working with Eli Lilly to launch Zepbound KwikPen

TIPRANKS
·
Apr 03

BRIEF-Ro Says Working With Eli Lilly To Launch Zepbound Kwikpen Nationwide On Its Platform

Reuters
·
Apr 03

Immunovant says Phase 3 batoclimab trials miss primary endpoint in thyroid eye disease

Reuters
·
Apr 02

Roivant’s Priovant starts Phase 2b/3 brepocitinib trial in lichen planopilaris

Reuters
·
Apr 02

Roivant Sciences Ltd - Phase 3 Studies of Batoclimab in Ted Fail to Meet Primary Endpoint

THOMSON REUTERS
·
Apr 02

Roivant Sciences Ltd: Topline Phase 3 Data in Niu and Phase 3 Study Initiation in Cs Are Expected in Second Half of Calendar Year 2026

THOMSON REUTERS
·
Apr 02